Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022.

Monkeypox epidemiology incubation period modelling poxvirus quarantine smallpox statistics symptom onset varicella virus infection (chickenpox)

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
06 2022
Historique:
entrez: 17 6 2022
pubmed: 18 6 2022
medline: 22 6 2022
Statut: ppublish

Résumé

In May 2022, monkeypox outbreaks have been reported in countries not endemic for monkeypox. We estimated the monkeypox incubation period, using reported exposure and symptom-onset times for 18 cases detected and confirmed in the Netherlands up to 31 May 2022. Mean incubation period was 9.0 [corrected] days (5th-95th percentiles: 4.2-17.3), underpinning the current recommendation to monitor or isolate/quarantine case contacts for 21 days. However, as the incubation period may differ between different transmission routes, further epidemiological investigations are needed.

Identifiants

pubmed: 35713026
doi: 10.2807/1560-7917.ES.2022.27.24.2200448
pmc: PMC9205160
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
J Infect Dis. 2006 Sep 15;194(6):773-80
pubmed: 16941343
Int J Hyg Environ Health. 2009 Jan;212(1):97-104
pubmed: 18178524
Euro Surveill. 2022 Jun;27(22):
pubmed: 35656830
PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141
pubmed: 35148313
Am J Epidemiol. 2003 Jul 15;158(2):110-7
pubmed: 12851223
Euro Surveill. 2022 Jun;27(22):
pubmed: 35656834

Auteurs

Fuminari Miura (F)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Center for Marine Environmental Studies (CMES), Ehime University, Ehime, Japan.

Catharina E van Ewijk (CE)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Jantien A Backer (JA)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Maria Xiridou (M)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Eelco Franz (E)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Eline Op de Coul (E)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Diederik Brandwagt (D)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Brigitte van Cleef (B)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Gini van Rijckevorsel (G)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Department of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.

Corien Swaan (C)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Susan van den Hof (S)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.

Jacco Wallinga (J)

Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC), Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH